We are live on ! Find out more
AZN icon

AstraZeneca

544 hedge funds and large institutions have $17.3B invested in AstraZeneca in 2018 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 151 increasing their positions, 197 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $225M | Put options by funds: $73.5M

38% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 47

23% more capital invested

Capital invested by funds: $14B → $17.3B (+$3.3B)

3% more funds holding

Funds holding: 530544 (+14)

1.19% more ownership

Funds ownership: 16.09%17.28% (+1.2%)

23% less repeat investments, than reductions

Existing positions increased: 151 | Existing positions reduced: 197

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
544
Holders Change
+14
Holders Change %
+2.64%
% of All Funds
12.44%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
65
Increased
151
Reduced
197
Closed
47
Calls
$225M
Puts
$73.5M
Net Calls
+$152M
Net Calls Change
+$45M
Name Holding Trade Value Shares
Change
Change in
Stake
IB
301
Intrust Bank
Kansas
$372K -$32.6K -431 -8%
BCM
302
Bluefin Capital Management
New York
$372K +$102K +1,350 +40%
CG
303
Cutler Group
California
$371K +$253K +3,350 +249%
CFB
304
Cullen/Frost Bankers
Texas
$360K -$756 -10 -0.2%
FCM
305
Flinton Capital Management
Pennsylvania
$360K
SMH
306
Sanders Morris Harris
Texas
$356K
WAM
307
Westport Asset Management
Connecticut
$350K
First Manhattan
308
First Manhattan
New York
$348K
LCM
309
LVM Capital Management
Michigan
$348K
MLFP
310
MPS Loria Financial Planners
Illinois
$345K -$4.01K -53 -1%
GAMC
311
Garner Asset Management Corp
Texas
$340K -$1.89K -25 -0.6%
Nisa Investment Advisors
312
Nisa Investment Advisors
Missouri
$340K +$325K +4,300 New
FCH
313
Freestone Capital Holdings
Washington
$337K +$322K +4,261 New
SCA
314
Snowden Capital Advisors
New York
$334K +$85.8K +1,134 +37%
SPC
315
Sigma Planning Corp
Michigan
$333K +$5.14K +68 +2%
IA
316
IFP Advisors
Florida
$332K +$832 +11 +0.3%
GC
317
Grimes & Company
Massachusetts
$331K -$13.2K -175 -4%
CB
318
Commerce Bank
Missouri
$330K -$67.4K -891 -18%
BA
319
Bristol Advisors
Pennsylvania
$324K +$310K +4,100 New
SCM
320
Sterling Capital Management
North Carolina
$318K -$4.84K -64 -2%
AAM
321
AR Asset Management
California
$317K
FC
322
FCA Corp
Texas
$317K
ACM
323
Aviance Capital Management
Florida
$316K +$302K +3,993 New
IRC
324
Investors Research Corp
Georgia
$315K
WS
325
Wedbush Securities
California
$313K -$13.8K -183 -4%

AZN Hedge Fund Activity: Q3 2018 in Review

544 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2018, worth a combined $17.3B — up 23% from $14B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new AZN positions and 47 closed out — a net gain of 18 holders — while 151 added to existing stakes and 197 trimmed.

The largest buyer was Jennison Associates, adding an estimated $774M. The largest seller was Bank of America, cutting an estimated $123M.

  • 544 institutional investors held AstraZeneca (AZN) as of Q3 2018, up from 530 in Q2 2018.
  • Funds reported $17.3B of AstraZeneca stock for Q3 2018, up 23% quarter-over-quarter.
  • 65 funds opened new AstraZeneca positions in Q3 2018 and 47 closed out, a net change of +18 holders.
  • The largest AstraZeneca buyer in Q3 2018 was Jennison Associates, an estimated $774M added.
  • The largest AstraZeneca seller in Q3 2018 was Bank of America, an estimated $123M sold.

Based on aggregated 13F filings for Q3 2018.